<<
>>

: . . .. - , .. , .. . .: , 2000. .. - . 1975; 20(6): 560-571.
.., .., -
. . . , - . , . 2004; 8/9: 21-24. .., .., .., .. . , . 2009; 54(1~2): 38~41. Amurrio ., Lewden S., Nicolas R. et al. Effect of treatment with clindamycin, erythromycin, rifamycin or gentamicin on the ingestion capacity of peritoneal macrophages in mice. Pathol. Biol. (Paris) 1990; 38: 13-18. Bellahsene A., Forsgren A. Effect of fusidic acid on the immune response in mice. Infect. Immun. 1980; 29: 873-878. Bendtzen K., Diamanf M., Faber V. Fusidic acid, an immunosuppressive drug with functions similar to cyclosporin A. Cytokine 1990; 2: 423-429. Bersani C., Bertoletfi R., Colombo M.L. et
al. In vitro and ex vivo influence of rifamy- cins on human phagocytes. Chemioterapia 1987; 6: 420-425. Bobadilla-Gonzalez P., Garcia-Menaya J.M., Cordobes-Duran C. et al. Generalized urticaria to fusidic acid. Allergy 2009; 64: 817-818. Brufani M. Anzamicins. In: Topics in antibiotics chemistry. New York, 1977; 1: 91-212. Christiansen K. Fusidic acid adverse drug reactions. Int. J. Antimicrob. Agents 1999; 12: 3-9. Christiansen K. Fusidic acid non-antibacterial activity. Int. J. Antimicrob. Agents 1999; 12: 73-78. Collignon P., Turnidge J. Fusidic acid in vitro activity. Int. J. Antimicrob. Agents 1999; 12: 45-58. De Castro Martinez F.J., Ruiz F.J., Tornero
P. et al. Systemic contact dermatitis due to fusidic acid. Contact. Dermat. 2006; 54: 169. Delgado A., Zaman S., Muthaiyan A. et al. The fusidic acid stimulon of Staphylococcus aureus. J. Antimicrob. Chemother. 2008; 62: 1207-1214. Doric M., Abram M., Rukavina T. Antimicrobial activity and immunological side effects of different antibiotics. Folia Biol. (Praha) 1993; 39: 162-165. EI-K.assarN., KalfonP., FromontP. etal. Fusidic acid induced acute immunologic thrombocytopenia. Br. J. Haematol. 1996; 93: 427-431. Forsgren A. Antimicrobial agents and host defence. Scand. J. Infect. Dis. Suppl. 1984; 43: 24-33.
Grassi G.G., Fietta A. Antibiotics and their interaction with the host defense system in vivo. J. Chemother. 1991; 3: 112-115. Helle A., Makifalo J., Huhtanen J. et at. Antibiotic fusidic acid has strong interactions with negatively charged lipid membranes: an electrokinetic capillary chromatographic study. Biochim. Biophys. Acta 2008; 1778: 2640-2647. Jiang Z.D., DuPont H.L. Rifaximin: in vitro and in vivo antibacterial activity-a review. Chemotherapy 2005; 51: 67-72. Ibrahim M.S., Maged Z.A., Haron A.
et al. Antibiotics and immunity: effects of antibiotics on natural killer, antibody dependent cell-mediated cytotoxicity and antibody production. Chemioterapia 1987; 6: 426-430. Ibrahim M.S., Maged Z.A., Haron A. et al. Antibiotics and immunity: effects of antibiotics on mitogen responsiveness of lymphocytes and interleukin-2 production. Chemioterapia 1988; 7: 369-372. IdreesF., JabeenK., KhanM.S., Zafar A. Antimicrobial resistance profile of methicillin resistant staphylococcal aureus from skin and soft tissue isolates. J. Pak. Med. Assoc. 2009; 59: 266-269. Kanellakopoulou K., Tselikos D., Giannitsioti E. et al. Pharmacokinetics of fusidic acid and cefepime in heart tissues: implications for a role in surgical prophylaxis. J. Chemother. 2008; 20: 468-471. Lannergard J., Norstrom T., Hughes D. Genetic determinants of resistance to fusidic acid among clinical bacteremia isolates of Staphylococcus aureus. Antimicrob. Agents Chemother. 2009; 53: 2059-2065. Liao Y.M., Chiu C.F., /VI.W., Hsueh C.T. Fusidic acid-induced leukopenia and thrombocytopenia. J. Chin. Med. Assoc. 2003; 66: 429-432. Liu C., Wang Z.Q., Li R., Sun X.G. Analysis on the susceptibility of fusidic acid for common gram positive bacteria. Zhonghua Yan Ke Za Zhi 2009; 45: 452-455. Mayo 1., Puchades F., de la Paz M.F. Topical fusidic acid for treatment of Clostridium per- fringens keratitis. Cornea 2008; 27: 959-960. Noren T., Wullt M., Akerlund T. et al. Frequent emergence of resistance in Clostridiumdifficile during treatment of C. difficile-associated diarrhea with fusidic acid. Antimicrob. Agents Chemother. 2006; 50: 3028-3032. OwenS.E. Findings cannot be extrapolated. BMJ 2002; 324: 1394. Pruzanski W., Saifo S. Influence of agents with immunomodulating activity on phagocytosis and bactericidal function of human polymorphonuclear cells. J. Rheumatol. 1983; 10: 688-693. Rastogi N., Labrousse V., Goh K.S. In vitro activities of fourteen antimicrobial agents against drug susceptible and resistant clinical isolates of Mycobacterium tuberculosis and comparative intracellular activities against the virulent H37Rv strain in human macrophages. Curr. Microbiol. 1996; 33: 167-175. Spelman D. Fusidic acid in skin and soft tissue infections. Int. J. Antimicrob. Agents 1999; 12: 59-66. Spisani S., Dovigo L., Corazza G. et al. The
effect of rifamycin SV on neutrophil functions in patients with rheumatoid arthritis. Scand. J. Rheumatol. 1982; 11: 65-69. Stoddart B. Problem may be clinically important. BMJ 2002; 324: 1394. Targowski T. Immunomodulating properties of antibiotics. Pol. Merkur. Lekarski 2004; 16: 88-90. Turnidge J. Fusidic acid pharmacology, pharmacokinetics and pharmacodynamics. Int. J. Antimicrob. Agents 1999; 12: 23-34. Turnidge J., Collignon P. Resistance to fusidic acid. Int. J. Antimicrob. Agents 1999; 12: 35-44. Van Vlem B., Vanholder R., De Paepe P. et al.
Immunomodulating effects of antibiotics: literature review. Infection 1996; 24: 275-291. Villa M.L., Rappocciolo G., Piazza P., Clerici E. The interference of antibiotics with antigen-specific antibody responses in man. Int. J. Immunopharmacol. 1986; 8: 805-809. Vosbeck K., James P.R., Zimmermann W. Antibiotic action on phagocytosed bacteria measured by a new method for determining viable bacteria. Antimicrob. Agents Chemother. 1984; 25: 735-741. Ziglam H.M., Daniels /., Finch R.G. Immunomodulating activity of rifampicin. J. Chemother. 2004; 16: 357-361.

~\




<< | >>
: .. , .. , .. . 2012. 2012

:

- - - -
- - - - - - - - - - - - - -